Lucaparib

Lucaparib (Rucaparib) Comprehensive Q&A Product Description

Lucaparib, known by its brand name Rucaparib, is an oral medication used primarily in the treatment of certain types of cancer, including ovarian cancer. It belongs to a class of drugs known as PARP inhibitors, which work by blocking the enzyme poly(ADP-ribose) polymerase (PARP). This action helps prevent cancer cells from repairing their damaged DNA, leading to cell death and tumor shrinkage.

Indications

Lucaparib is indicated for the treatment of patients with recurrent ovarian cancer who have been treated with two or more prior lines of chemotherapy and have a deleterious BRCA mutation. It is also used in maintenance therapy for patients with platinum-sensitive ovarian cancer.

Mechanism of Action

As a PARP inhibitor, Lucaparib targets cancer cells that are already compromised in their ability to repair DNA. By inhibiting PARP, it prevents the repair of single-strand breaks in DNA, leading to the accumulation of DNA damage and ultimately resulting in cell death, particularly in tumor cells with BRCA mutations.

Dosage and Administration

The recommended dosage of Lucaparib varies based on the patient's specific condition and prior treatments. It is usually taken orally, twice daily, with or without food. Patients should follow their healthcare provider's instructions regarding dosing and duration of treatment.

Side Effects

Common side effects of Lucaparib may include nausea, fatigue, decreased appetite, and anemia. More serious side effects can occur, such as liver enzyme elevation and myelodysplastic syndrome. Regular monitoring by a healthcare professional is essential to manage any adverse effects effectively.

Drug Interactions

Lucaparib may interact with other medications, including certain chemotherapy agents and drugs that affect liver enzymes. It is important for patients to inform their healthcare provider of all medications they are taking to avoid potential interactions.

Patient Considerations

Before starting Lucaparib, patients should discuss their complete medical history with their healthcare provider, particularly any history of liver disease or blood disorders. Women who are pregnant or breastfeeding should avoid using this medication due to potential risks to the fetus or infant.

Conclusion

Lucaparib (Rucaparib) represents a targeted therapy option for patients with specific types of ovarian cancer. Its mechanism of action and effectiveness in patients with BRCA mutations make it a significant advancement in cancer treatment. Patients should work closely with their healthcare team to ensure safe and effective use of this medication.